A218 THE RISK OF RECURRENT HEPATOCELLULAR CARDINOMA IN POST-LIVER TRANSPLANT PATIENTS RECEIVING CAPECITABINE TREATMENT

BACKGROUND: Little is known on how to reduce the risk of hepatocellular carcinoma (HCC) recurrence post liver transplantation (LT). We examined if adjuvant oral Capecitabine reduces the risk of recurrent HCC in a high-risk group post-LT. AIMS: To examine if adjuvant oral Capecitabine reduces the ris...

Descripción completa

Detalles Bibliográficos
Autores principales: Alsager, M, Chaitanya, V, Gandhi, R, Puka, K, Tang, E, Teriaky, A, Qumosani, K, Skaro, A, Parfitt, J, Brahmania, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Poster of Distinction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859396/
http://dx.doi.org/10.1093/jcag/gwab049.217

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859396/
http://dx.doi.org/10.1093/jcag/gwab049.217

Ejemplares similares